Advanced Oncotherapy Regulatory News (AVO)

4 December 2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy", "AVO" or "the Company")

Advanced Oncotherapy supports Collider Exhibition at the

Science Museum in London

Advanced Oncotherapy plc (AIM: AVO) announces its support of the Large Hadron Collider Exhibition at the Science Museum, London. http://www.sciencemuseum.org.uk/collider

The Collider exhibition allows visitors to look behind the scenes at the CERN particle physics laboratory where some of the scientists who helped develop the Large Hadron Collider (LHC) are those behind Advanced Oncotherapy's new technology for cancer treatment with protons, LIGHT. The exhibition uses video and sound installations alongside theatrics to create a truly immersive experience and allows visitors to explore the Higgs boson discovery and creates a window into the lives of the particle physicists. The Collider exhibition was opened by Professor Peter Higgs, winner of the 2013 Nobel Prize for Physics and Professor Stephen Hawking.

Advanced Oncotherapy recently completed its acquisition of ADAM, the first CERN medical spin-off in the UK. AVO's new linear accelerator technology - LIGHT - uses protons in radiotherapy to kill cancer more precisely and will revolutionise the way clinicians globally treat a range of cancers. Treatment with protons causes much less damage to healthy tissues than conventional radiation with x-rays and the LIGHT equipment is a fraction of the cost and size of current proton therapy equipment. Operations are located in the UK and at the CERN Campus in Switzerland.

Director of the Science Museum, Ian Blatchford, said"The Science Museum is extremely appreciative of the generous sponsorship received for our Collider Exhibition. At the launch ceremony, I mentioned how thrilled we are that one of the sponsors, Advanced Oncotherapy, is applying the research behind the LHC to medical use in treating cancer. AVO is also a British company and their work reinforces the strong connections that the UK has had with CERN since its establishment."

Adam Afriyie, Conservative MP for Windsor and Chairman of the Parliamentary Office of Science &Technology (POST) commented at the launch receptions at Portcullis House: "The UK has been a major contributor to CERN for almost 60 years, so it is great that the Science Museum is running a new Collider exhibition that will inspire future generations of scientists and engineers. It is huge bonus that British companies are taking commercial advantage of the research coming out of CERN in areas such as irradiation, metallurgy, and oncology. We should never underestimate the power of science to solve difficult problems and kick-start the economy."

The Collider Exhibition is open at the London Science Museum until 6 May 2014. Tickets are available by calling 0870 870 4868 or visiting:

http://www.sciencemuseum.org.uk/visitmuseum/prices.aspx

The Collider Exhibition is supported by the Science & Technology Facilities Council, Winton Capital Management, the Embassy of Switzerland in the United Kingdom and Advanced Oncotherapy.

For more information on LIGHT and why treatment with protons is the next generation of radiation treatment for cancer patients, please visit http://www.avoplc.com or contact:

-ENDS-

Notes to Editors:

About Advanced Oncotherapy plc

1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT. This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK through Spire and other hospitals.

About POST

POST is Parliament's in-house source of independent, balanced and accessible analysis of public policy issues related to science and technology. POST's aim is to help parliamentarians examine science and technology issues effectively. By writing briefings, organising events and assisting Select Committees, we have supported parliamentarians in their decision-making since 1989. http://www.parliament.uk/post

About The Science Museum

As the home of human ingenuity, the Science Museum's world-class collection forms an enduring record of scientific, technological and medical achievements from across the globe. Welcoming over 3 million visitors a year, the Museum aims to make sense of the science that shapes our lives, inspiring visitors with iconic objects, award-winning exhibitions and incredible stories of scientific achievement. http://www.sciencemuseum.org.uk